Company

Prof. Dr. Joshua Lo is Chief Executive Officer of Leo International Precision Health AG, bringing more than 30 years of international leadership experience across technology, industry, and finance. He is a veteran corporate strategist with a proven record of large-scale organizational leadership, revenue growth, and cross-border capital markets execution. He combines deep capital markets expertise with a strong track record in corporate strategy, organizational scaling, and leading complex organizations.

He has served as Chief Executive Officer of five publicly listed companies in Germany and Taiwan, overseeing organizations operating across Asia, Europe, and the United States, in addition to holding President and Chairman roles in publicly listed and private multinational companies. Across these roles, he has led organizations with workforces exceeding 1,800 employees and managed business volumes of up to NTD 384 billion. Over the course of his executive career, Prof. Dr. Lo has successfully executed eight technology and financial M&A transactions in the United States, the United Kingdom, and Taiwan, including acquisitions, restructurings, and strategic integrations. These transactions include landmark integrations in both technology and banking sectors. Most recently, he has completed acquisitions of six majority shareholdings of AI-driven asset companies via a capital raise against contribution in kind for Leo International Precision Health AG.

Prior to joining Leo International Precision Health AG, Prof. Dr. Lo led Portwell Technology Group (TWSE: 6105), a globally active industrial computing company, and held senior leadership roles in industrial manufacturing, IoT, and smart technology businesses. Earlier in his career, he held executive positions at leading international financial institutions, including Citigroup, Standard Chartered Bank, and ABN AMRO, where he was involved in capital markets transactions, structured finance, cross-border mergers and corporate transformations. Across his career in the financial sector, he generated cumulative asset growth of approximately NTD 800 billion.

Alongside his corporate career, Prof. Dr. Lo is an EMBA and Management PhD professor specializing in capital markets, business model innovation, and strategic management at leading universities in Taiwan. He actively bridges academic research with real-world corporate governance and capital markets practice. He holds two doctoral degrees in Management and Communication and has received numerous significant industry and academic awards recognizing executive leadership, technological innovation, and corporate transformation,  including the Taiwanese government’s "Taiwan Innovation" and “Best International Development” award as well as the “Excellent SME", "Best Business and Product", "National Branding" award and recognition as a “Spotlight Executive” nomination by the Taipei Stock Exchange.

Phillip Campbell is Chief Financial Officer of Leo International Precision Health AG, bringing more than two decades of experience in finance, tax, and legal advisory across corporate, transactional, and capital markets environments. He combines deep financial expertise with a strong legal background and a clear focus on governance, compliance, and value-oriented financial management.

Prior to and alongside his role at Leo International Precision Health AG, Mr. Campbell has held senior leadership and partner positions at leading German legal and tax advisory firms, including Campbell Hörmann Rechtsanwälte & Steuerberater, bks partners GmbH Steuerberatungsgesellschaft, and CdC Capital GmbH Steuerberatungsgesellschaft, where he has advised corporates and entrepreneurs on complex tax, corporate, and transaction-related matters. Earlier in his career, he served as Chief Financial Officer of TEEC GmbH and worked as a lawyer at LKC Kemper Czarske v. Gronau Berz, gaining broad operational, financial, and capital-markets experience across multiple industries.

Mr. Campbell is admitted to the German bar and has been a certified tax advisor since 2009. He regularly acts as a speaker and lecturer in tax law and has completed advanced executive leadership training. His international background and dual German–U.S. nationality support his work in cross-border structures and capital markets contexts.

Gary Cheng is Chief Operating Officer and a member of the Executive Management Board of Leo International Precision Health AG, bringing more than 30 years of international leadership experience across banking, capital markets, and corporate operations in Europe, Greater China, and Southeast Asia. He combines deep operational expertise with a strong understanding of corporate governance, M&A, compliance and capital markets in a cross-border setting.

Prior to joining Leo International Precision Health AG, Mr. Cheng held senior executive roles at leading financial institutions and investment platforms. He served as Regional Chief Executive for Southeast Asia, General Manager for Taiwan, and Deputy General Manager for the UK at The Bank of East Asia, overseeing multi-jurisdictional operations and regulatory relationships. More recently, he was Group CFO of Deluxe Technology Co. and continues to serve as a Partner at Canaan Capital/TXI Center, focusing on private equity, ESG-driven investments and fundraising and serves as Director and Supervisor of the equity investments.

At Leo International Precision Health AG, Mr. Cheng oversees group operations, governance frameworks, and cross-border corporate development, including compliance, risk management, and integration of international assets. He holds an MBA from Heriot-Watt University, Edinburgh, and a BSc in Economics from the University of London, and brings an international background alongside his Singapore nationality, enabling him to bridge operational execution with capital markets and growth objectives.